Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two initial faricimab loading doses in treatment-naive neovascular AMD
2024-514408-15-00Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Medical University of Graz. Primary endpoint: Proportion of patients without disease activity at week 8. Started Oct 2024; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-514408-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514408-15-00.